GSK plc

GSK plc Debt

The Debt of GSK plc (GSK.L) as of Nov 3, 2026 is 17.72 B GBP. In the previous year, Debt was 16.99 B GBP — a change of 4.32% (higher).

Debt

17.72 BGBP

YoY

4.32%

Last updated:

In 2025, GSK plc's total debt was 17.72 B GBP, a 4.32% change from the 16.99 B GBP total debt recorded in the previous year.

The GSK plc Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt
Date
Debt
Jan 1, 2018
26.06 B GBP
Jan 1, 2019
30.51 B GBP
Jan 1, 2020
27.15 B GBP
Jan 1, 2021
24.17 B GBP
Jan 1, 2022
20.99 B GBP
Jan 1, 2023
18.02 B GBP
Jan 1, 2024
16.99 B GBP
Jan 1, 2025
17.72 B GBP
The GSK plc Debt history
YEARDebtYoY
17.72 BGBP+4.32%
16.99 BGBP-5.73%
18.02 BGBP-14.15%
20.99 BGBP-13.18%
24.17 BGBP-10.97%
27.15 BGBP-11.01%
30.51 BGBP+17.05%
26.06 BGBP+52.52%
17.09 BGBP-9.05%
18.79 BGBP+12.97%
16.63 BGBP-11.46%
18.78 BGBP—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

GSK plc Stock analysis

What does GSK plc do? GSK plc generates revenue through its Pharmaceuticals and Vaccines segments, which focus on developing and selling prescription medicines and vaccines. The Pharmaceuticals segment offers products in Respiratory, HIV, Specialty, and Classic and Established categories, targeting acute and chronic diseases. The Vaccines segment provides over 40 vaccines for pediatric, adolescent, adult, and older populations, including travel vaccines. Customers include healthcare providers, hospitals, and consumers purchasing over-the-counter products. GSK's brand portfolio spans prescription medicines like those for Respiratory and HIV, alongside vaccines such as those for pediatric and adult health. The company's research focuses on six therapeutic areas: Respiratory diseases, HIV/infectious diseases, Vaccines, Immuno-inflammation, Oncology, and Rare diseases. This research drives product development for both segments, ensuring a steady pipeline of medicines and vaccines. The company's products are distributed globally, with the Pharmaceuticals business targeting healthcare professionals and the Vaccines business serving public health programs and individual consumers. GSK's strategy emphasizes innovation in key therapeutic areas to address unmet medical needs, leveraging its extensive research and development capabilities to maintain market leadership. GSK plc is one of the most popular companies on Eulerpool.

Debt Details

Understanding GSK plc's Debt Structure

GSK plc's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing GSK plc's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to GSK plc’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in GSK plc’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about GSK plc stock

Debt of GSK plc is 17.72 B GBP in 2025.

Debt of GSK plc changed from 16.99 B GBP to 17.72 B GBP, representing a 4.32% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Debt GSK plc since 2006 – with annual values, charts, and detailed analysis.

Debt's GBP is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Debt's GSK plc historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — GSK plc

All Key Metrics — GSK plc